Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5900856 | 0.98 | GABRP (0.38) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Trifluoroacetic Acid SCHEMBL3006963 | 0.87 | GABRP (0.35) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL12141387 | 0.87 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL583936 | 0.87 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL1972543 | 0.87 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL21590701 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL28302032 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL21989907 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL21772806 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL29435243 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | claimed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12391667-B2 | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-19 | — | — | US | disclosed |
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-4050006-B1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024216229-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-0413405-A2 | Use of amide complex compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-02-20 | — | — | EP | disclosed |
| EP-0336879-A1 | Meso-tetraphenylporphyrin complex compounds,process for their preparation and pharmaceuticals containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-10-11 | — | — | EP | disclosed |
| EP-0263059-A2 | Complexes amides | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-04-06 | — | — | EP | disclosed |
| EP-0255471-A1 | 1,4,7,10-Tetraazacyclododecane-derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-02-03 | — | — | EP | disclosed |
| EP-0250358-A2 | Novel complex compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-12-23 | — | — | EP | disclosed |
| US-4396765-A | ANTIASTHMATICS, BRONCHODILATORS | STERLING DRUG INC. (US) | 1983-08-02 | — | — | US | disclosed |
| US-4339576-A | Anti-asthmatic, anti-allergic, anti-cholinergic, bronchodilator and anti-inflammatory 1-[(benzoylphenyl)-lower-alkyl]piperidines and analogs thereof | STERLING DRUG INC. (US) | 1982-07-13 | — | — | US | disclosed |
| EP-0052311-A1 | 1-((Benzoylphenyl) - lower-alkyl) piperidines and carbinol analogs and preparation thereof | STERLING DRUG INC. (US) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | GABRA1 4518/4885TSHR 3503/4885GABRG2 4469/4885 |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | GABRA1 2034/4885TSHR 822/4885GABRG2 2174/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | GABRA1 2816/4885TSHR 4267/4885GABRG2 3488/4885 |
| US-12391667-B2 | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases | ENPP2, MYT1, INMT | GABRA1 4637/4885TSHR 2504/4885GABRG2 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.